Tid: 2018-11-15 Kl 15:00
Plats: Location: Inspira, Medicon Village, Scheelevägen 2 Lund
Kontakt: Kristian Pietras, Kristian.Pietras@med.lu.se
Title: ”Receptor tyrosine kinase signaling in metastatic breast cancer”
Speaker: Prof Morag Park, McGill University, Toronto, Canada
Host: Kristian Pietras
Dr. Morag Park is a full Professor in the Departments of Biochemistry, Medicine and Oncology at McGill University. She is the Director of the Rosalind and Morris Goodman Cancer Research Centre and has served as the Scientific Director of the CIHR Institute of Cancer Research, Director of the McGill Molecular Oncology Group and Joint Head of the Cancer Axis at MUHC. She is a Fellow of the Royal Society of Canada and holds the Diane and Sal Guerrera Chair in Cancer Genetics.
Dr. Park’s research interests focus on the molecular mechanisms of oncogenic activation of receptor tyrosine kinases and mechanisms for cell transformation using the Met, hepatocyte growth factor (HGF) and oncoprotein as a model. Our group and others have shown that the activity of the HGF receptor is frequently altered in human cancer and have proposed new models for its mechanism of oncogenic activation. Our current work is aimed at identifying the critical molecular signals regulated by the HGF/SF receptor and receptor tyrosine kinases, in general, that contribute to tumor progression, and are suitable targets for therapeutic intervention. We have developed epithelial as well as fibroblastic and mouse models, to study at the molecular level, signals required for epithelial morphogenesis and those signals that promote the breakdown of organized epithelial structures, anchorage independent growth, tumorigenesis and invasion.
"KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer."
Knight JF, Sung VYC, Kuzmin E, Couzens AL, de Verteuil DA, Ratcliffe CDH, Coelho PP, Johnson RM, Samavarchi-Tehrani P, Gruosso T, Smith HW, Lee W, Saleh SM, Zuo D, Zhao H, Guiot MC, Davis RR, Gregg JP, Moraes C, Gingras AC, Park M.
Cell Rep. 2018 Mar 20;22(12):3191-3205. doi: 10.1016/j.celrep.2018.02.095.
"Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer."
Saleh SMI, Bertos N, Gruosso T, Gigoux M, Souleimanova M, Zhao H, Omeroglu A, Hallett MT, Park M.
Cancer Res. 2017 Sep 1;77(17):4673-4683. doi: 10.1158/0008-5472.CAN-16-3427. Epub 2017 Jun 26.
"Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer."
Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M.
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10. doi: 10.1073/pnas.1210353110. Epub 2013 Mar 18.
"Stromal gene expression predicts clinical outcome in breast cancer"
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M.
Nat Med. 2008 May;14(5):518-27. doi: 10.1038/nm1764. Epub 2008 Apr 27.